SymBiosis Capital Partners, LLC
An institutional investment manager in BENTONVILLE, AR. Its Form 13F for the quarter ended Mar 31, 2026, filed May 12, 2026. SEC CIK 2006045.
- Reported value$52.8m
- Positions6
Holdings: 6 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. The manager did not file for the quarter before, so changes are not compared.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Evommune, Inc.EVMN | COM SHS | 30054Y107 | 29.4 | 55.8% | 1,280,778 | Not compared | |
| Inventiva S.A.IVA | ADS | 46124U107 | 13.1 | 24.8% | 2,354,000 | Not compared | |
| Wave Life Sciences Ltd. | SHS | Y95308105 | 5.4 | 10.3% | 750,000 | Not compared | |
| Rani Therapeutics Holdings, Inc.RANI | COM CL A | 753018100 | 2.7 | 5.1% | 3,667,585 | Not compared | |
| Clene Nanomedicine Inc.CLNN | COM NEW | 185634201 | 2.1 | 4.0% | 431,094 | Not compared | |
| Surrozen, Inc. | *W EXP 08/01/203 | 86889P117 | 0.0 | <0.1% | 150,000 | Not compared |
Source: SEC EDGAR, Form 13F-HR, accession 0002006045-26-000007 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.